Stockpolly
Search
APLM · NASDAQ · Biotechnology

Apollomics (APLM)

Develops vebreltinib and other oncology candidates through global trials and territorial partnerships.

$27.35
At close+0.41 (+1.52%)
Watchlist

In millions of USD, except per-share figures

In millionsQ2 FY20Jun 2020Q4 FY20Dec 2020Q2 FY21Jun 2021Q4 FY21Dec 2021Q2 FY22Jun 2022Q4 FY22Dec 2022Q2 FY23Jun 2023Q4 FY23Dec 2023Q2 FY24Jun 2024Q4 FY24Dec 2024Q2 FY25Jun 2025Q4 FY25Dec 2025
Revenue200010002−290
Cost of revenue000000000000
Gross profit200010002−290
2814252523222629271519−1
Research & development22918171817171817851
657855101110814−2
General & administrative11078551011108140
Operating income−27−14−25−25−23−23−26−28−25−17−111
−17−17−41−319−215−1256−10−2−20
Interest income000000000000
Interest expense000000000000
Other non-operating income−17170−10−1000−120
Income before tax−43−32−66−28−3−237−151−22−35−18−132
Income tax expense000000000000
Net income from continuing operations−43−32−66−28−3−237−151−22−35−19−132
Net income−43−32−66−28−3−237−151−22−35−19−132
EPS, basic−$20.61−$0.09−$0.18−$1.28−$0.05−$0.00−$2.56−$0.24−$37.56−$16.92−$11.37$3.80
EPS, diluted−$20.61−$0.09−$0.18−$1.28−$0.05−$0.00−$2.56−$0.24−$38.00−$16.92−$11.37$3.80
Weighted average shares, basic144001111110
Weighted average shares, diluted144001111110
EBITDA−9−31−25−25−22−21−26−28−25−16−133
Depreciation & amortization000000000000
EBIT−9−32−25−25−23−22−26−28−25−16−133